Please assess the completion status of the following clinical trial:

Trial Title: Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients at least 18 years of age~* Receiving Wake Forest Baptist Health Outpatient parenteral antimicrobial therapy (OPAT) services~* Will receive vancomycin therapy from Wake Forest Baptist Health Specialty Home Infusion Pharmacy~* Planned therapy with vancomycin in the outpatient setting for at least 2 weeks in duration~* Prescribed vancomycin with a frequency of either every 12 hours or every 8 hours dosing at the time of enrollment~Exclusion Criteria:~* Presence of diseases or conditions known to affect the pharmacokinetics of vancomycin: Pregnancy/Ascites/Burn injury/Cystic fibrosis /Weight greater-than or equal-to 150 kg~* Pre-existing leukopenia: White Blood Cell (WBC) \< 4,000 x 103 cells/µL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- continuous infusions (CI) group (Type: ACTIVE_COMPARATOR): CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge
- Intermittent infusion (II) group (Type: ACTIVE_COMPARATOR): Inpatient study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).